

## MARCH

Date	Headline and Source	Link	Summary
1 <sup>st</sup> March	Bristol Myers CEO says India to have largest R&D presence outside US by 2025 CNBC TV18, March 01, 2024	<a href="#">Bristol Myers CEO says India to have largest R&amp;D presence outside US by 2025</a>	US drugmaker Bristol Myers Squibb aims to expand its research and development presence in India and expects its newly inaugurated Hyderabad facility to become its largest unit outside the US by 2025, CEO Christopher Boerner said. Share Market Live NSE View All View All
1 <sup>st</sup> March	GSK Survey Reveals Alarming Lack of Awareness About Shingles BW Healthcare World, March 01, 2024	<a href="#">GSK Survey Reveals Alarming Lack of Awareness About Shingles</a>	GlaxoSmithKline (GSK) recently released survey highlights a significant gap in understanding shingles risk among adults aged 50 and over. The survey, which involved 3,500 participants from 12 countries, including 500 from India, revealed that 83.5 per cent of Indian respondents underestimate their risk of developing shingles.
1 <sup>st</sup> March	India s redundant policies obstruct entry of new global medicines into its market: Eli Lilly CEO Dave Ricks Business Today, March 01, 2024	<a href="#">India s redundant policies obstruct entry of new global medicines into its market: Eli Lilly CEO Dave Ricks</a>	Dave Ricks, chief executive officer (CEO) of Eli Lilly and Company, spoke to BT on the sidelines of BioAsia 2024, a life science and healthcare forum organised by the Government of Telangana that concluded on Wednesday. He talked about India s vital role in the global life sciences sector, Eli Lilly's India focus, and the way forward.
1 <sup>st</sup> March	Roche Pharma unveils multiple sclerosis treatment drug Ocrevus in India Medical Dialogues, March 01, 2024	<a href="#">Roche Pharma unveils multiple sclerosis treatment drug Ocrevus in India</a>	Roche Pharma India has launched a drug for the treatment of Multiple Sclerosis (MS), expanding its neurology portfolio to cater to unmet needs of patients grappling with the disease. The company has introduced Ocrevus (Ocrelizumab) which is the first and only approved disease modifying therapy for both Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS).
1 <sup>st</sup> March	Sanofi India Ltd drops for fifth straight session Business Standard, March 01, 2024	<a href="#">Sanofi India Ltd drops for fifth straight session</a>	Sanofi India Ltd is quoting at Rs 8686.05, down 1.8% on the day as on 13:19 IST on the NSE. The stock jumped 13.4% in last one year as compared to a 25.87% rally in NIFTY and a 60.77% spurt in the Nifty Pharma index. Sanofi India Ltd fell for a fifth straight session today.
1 <sup>st</sup> March	Takeda to soon start trials in India for dengue vaccine	<a href="#">Takeda to soon start trials in India for dengue vaccine</a>	Takeda Pharmaceuticals dengue vaccine assumes significance since the first vaccine ever licensed for dengue,

	The Economic Times, March 01, 2024		developed by French drugmaker Sanofi Pasteur, met with failure as it only helped people who had been previously infected with the virus Takeda Pharmaceuticals dengue vaccine has been tested globally on about 28,000 participants across phase 1, 2 and 3 trials, including the pivotal phase 3 tetravalent immunisation against dengue efficacy study trial
2 <sup>nd</sup> March	-	-	-
3 <sup>rd</sup> March	-	-	-
4 <sup>th</sup> March	AI can bring transformational medicines; India has incredible talent pool: Bristol Myers CEO The Economic Times, March 04, 2024	<a href="#">AI can bring transformational medicines; India has incredible talent pool: Bristol Myers CEO</a>	Bristol Myers Squibb (BMS) CEO Christopher Boerner climbed to the top of his organisation just four months ago. Prior to that, he held a range of leadership roles. His stint coincides with what BMS describes as a “period of renewal” or a slow-growth phase until it sees a maximising performance from 2025.
4 <sup>th</sup> March	Maker of spurious antibiotics busted in Uttarakhand, big pharma companies exploited CNBC TV18, March 04, 2024	<a href="#">Maker of spurious antibiotics busted in Uttarakhand, big pharma companies exploited</a>	Brands such as GlaxoSmithKline (GSK), Alkem Laboratories, Aristo Pharmaceuticals, and Cipla were among those exploited by Nectar Herbs & Drugs, according to the DCA. Notably, counterfeit versions of popular medications like Augmentin 625, Calvum-625, Omnicef-O 200, and Montclair LC were being produced at the illicit facility.
5 <sup>th</sup> March	Targeted funding strategies and policy interventions are key to make rare disease treatments affordable Express Pharma, March 05, 2024	<a href="#">Targeted funding strategies and policy interventions are key to make rare disease treatments affordable</a>	As OPPI, we advocate for inclusive funding for the treatment of patients with rare diseases, regardless of the specific disease groups they fall into and to put in place a mechanism to streamline the utilisation of funds to ensure those in need are not denied access for non-utilisation of available funds.
5 <sup>th</sup> March	Novo Nordisk & Embassy REIT Launch 'NovoHealth@EmbassyManyata' For Employee Wellness In Bangalore BW Healthcare World, March 05, 2024	<a href="#">Novo Nordisk &amp; Embassy REIT Launch 'NovoHealth@EmbassyManyata' For Employee Wellness In Bangalore</a>	The Novo Nordisk Education Foundation (NNEF) and Embassy REIT, Asia's largest office REIT, have joined forces to introduce a pioneering health and fitness program, "NovoHealth@EmbassyManyata," aimed at enhancing the well-being of over 1,00,000 employees working at Embassy Manyata Business Park in North Bengaluru.
6 <sup>th</sup> March	Roche Pharma launches Vabysmo to treat vision impairment Live Mint, March 06, 2024	<a href="#">Roche Pharma launches Vabysmo to treat vision impairment</a>	Roche Pharma India, a subsidiary of Swiss pharmaceutical giant Roche, has launched Vabysmo (faricimab) in the Indian market. This monoclonal antibody drug targets two significant causes of

			vision loss among the elderly and diabetic patients.
6 <sup>th</sup> March	Submit Post Marketing Safety Data of Indians: CDSCO Panel Tells Novo Nordisk on Semaglutide Warning Statement Medical Dialogues, March 06, 2024	<a href="#">Submit Post Marketing Safety Data of Indians: CDSCO Panel Tells Novo Nordisk on Semaglutide Warning Statement</a>	In response to the proposal presented by the drug major Novo Nordisk for the amendment in the warning statement for the antidiabetic drug Semaglutide, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to submit post-marketing safety data of the Indian population.
6 <sup>th</sup> March	Roche forays into Indian ophthalmology space The Times of India, March 06, 2024	<a href="#">Roche forays into Indian ophthalmology space</a>	Swiss pharma giant Roche on Tuesday announced its foray into the ophthalmology space in India with the rollout of the world's first bispecific antibody, Faricimab, for the treatment of neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME).Faricimab, which was first approved by the USFDA in January 2022 and is now available in over 90 countries globally, has seen over 2 million doses being administered till date.
6 <sup>th</sup> March	Novo Nordisk Education Foundation, Embassy REIT partner to champion cause of Health at Workplace ET Health World, March 06, 2024	<a href="#">Novo Nordisk Education Foundation, Embassy REIT partner to champion cause of Health at Workplace</a>	Novo Nordisk Education Foundation (NNEF) and Embassy REIT have come together in a partnership to champion the cause of Health at Workplace for over 1,00,000 employees working at Embassy Manyata Business Park located in North Bengaluru.
6 <sup>th</sup> March	SEC recommends approval for AstraZeneca's ant hyperkalaemia drug Lokelma in India PharmaBiz, March 06, 2024	<a href="#">SEC recommends approval for AstraZeneca's ant hyperkalaemia drug Lokelma in India</a>	The Subject Expert Committee (SEC) which advises the national drug regulator on drug approvals and clinical trials has recommended grant of permission to drug major AstraZeneca for import and marketing of two strengths of anti-hyperkalaemia therapy drug Lokelma (sodium zirconium cyclosilicate for oral suspension).
7 <sup>th</sup> March	Roche forays into Indian ophthalmology space with rollout of worlds 1st bispecific antibody Faricimab The Times of India, March 07, 2024	<a href="#">Roche forays into Indian ophthalmology space with rollout of worlds 1st bispecific antibody Faricimab</a>	Swiss pharma giant Roche on Tuesday announced its foray into the ophthalmology space in India with the rollout of the world's first bispecific antibody, Faricimab , for the treatment of neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME).
7 <sup>th</sup> March	Ozempic reduces severity of liver disease in people with HIV, study shows	<a href="#">Ozempic reduces severity of liver disease in people with HIV, study shows</a>	Integrase strand transfer inhibitors have shown to be effective for suppressing HIV, but are also associated with weight gain in

	ET Health World, March 07, 2024		some patients. Eli Lilly's tirzepatide, the active ingredient in its popular diabetes drug Mounjaro, helped up to 74 per cent of patients achieve absence of a severe type of fatty liver disease with no worsening of liver scarring at 52 weeks in a mid-stage trial.
8 <sup>th</sup> March	AstraZeneca gets CDSCO Panel Nod To update Prescribing Information of Antidiabetic FDC Medical Dialogues, March 08, 2024	<a href="#">AstraZeneca gets CDSCO Panel Nod To update Prescribing Information of Antidiabetic FDC</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to AstraZeneca to update the prescribing information for the fixed-dose combination (FDC) antidiabetic drug Saxagliptin plus Dapagliflozin filmcoated tablet with the modification under special warning and precautions for use as If a patient presents with severe joint pain after starting the drug, continuation of drug therapy should be individually assessed.
8 <sup>th</sup> March	Transition times in the pharma universe Express Pharma, March 08, 2024	<a href="#">Transition times in the pharma universe</a>	The February 16 announcement of Novartis strategic review of its India subsidiary, including an assessment of the shareholding of Novartis AG in Novartis India, is the latest sign of MNC pharma's recalibration of strategic plans for one of the largest pharma markets.
8 <sup>th</sup> March	Roche has introduced Vabysmo (faricimab), the first and only bispecific monoclonal antibody Afternoon News, March 08, 2024	<a href="#">Roche has introduced Vabysmo (faricimab), the first and only bispecific monoclonal antibody</a>	Roche Pharma India has launched Vabysmo (faricimab) for the treatment of neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME), two leading causes of vision loss worldwide. Vabysmo is the first and only dual pathway inhibitor that targets and inhibits two disease pathways linked to a number of vision threatening retinal conditions.
8 <sup>th</sup> March	Veeda Clinical Research names Mahesh Bhalgat as group CEO The Economic Times, March 08, 2024	<a href="#">Veeda Clinical Research names Mahesh Bhalgat as group CEO</a>	Prior to joining Veeda, Bhalgat was heading operations of Syngene International, India's largest contract research, development and manufacturing organisation as chief operating officer. Mahesh has vast experience of being in senior leadership roles in Amgen, Sanofi and Biological E.
9 <sup>th</sup> March	AstraZeneca bets on licencing deals, public-private partnerships for India growth The Economic Times, March 09, 2024	<a href="#">AstraZeneca bets on licencing deals, public-private partnerships for India growth</a>	British-Swedish drugmaker AstraZeneca is in the process of 15 new launches in India including novel products and new indications of existing assets in two years, said Sanjeev Panchal, managing director of AstraZeneca Pharma India. We would

			be doing 15 new launches starting 2023 until 2025, he told ET.
9 <sup>th</sup> March	Seeing the demand, the competition to make obesity medicines increased, 70 companies joined hands Dainik Bhaskar, March 09, 2024	<a href="#">Seeing the demand, the competition to make obesity medicines increased, 70 companies joined hands</a>	The business of major obesity medicine manufacturing companies Novo Nordisk and Eli Lilly is running at a fast pace. The market value of V Gaani maker Novo Nordisk has increased by 87% to Rs 46 lakh crore since the beginning of 2023. It became the most valuable company in Europe.
10 <sup>th</sup> March	Who was Ranjit Shahani: A titan in India's pharmaceutical, business landscape. Know his contributions and more Live Mint, March 10, 2024	<a href="#">Who was Ranjit Shahani: A titan in India's pharmaceutical, business landscape. Know his contributions and more</a>	Shahani's expertise transcended pharmaceuticals, showcasing his diverse interests and contributions. In addition to his corporate positions, he held the esteemed titles of President Emeritus of the Organisation of Pharmaceutical Producers of India (OPPI) and President of the Swiss Indian Chamber of Commerce India.
10 <sup>th</sup> March	Pharma veteran Ranjit Shahani, key figure in benchmark Glivec case, passes away at 74 The Hindu Business Line, March 10, 2024	<a href="#">Pharma veteran Ranjit Shahani, key figure in benchmark Glivec case, passes away at 74</a>	Fake medicines was another subject close to his heart "the perfect murder", he called it, where the person died of the illness and evidence was lost. Shahani wore several hats, including President Emeritus of Organisation of Pharmaceuticals Producers of India (OPPI a platform for multinational drugmakers) and Chairman of JB Chemicals & Pharmaceuticals.
10 <sup>th</sup> March	AstraZeneca gets CDSCO Panel Nod To Import, Market Sodium Zirconium Cyclosilicate Powder for Oral Suspension Medical Dialogues, March 10, 2024	<a href="#">AstraZeneca gets CDSCO Panel Nod To Import, Market Sodium Zirconium Cyclosilicate Powder for Oral Suspension</a>	Noting an unmet medical need, the Subject Exper Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug major AstraZeneca to import and market Sodium Zirconium Cyclosilicate powder for oral suspension (Lokelma 5g and 10g).
10 <sup>th</sup> March	USFDA approves Opdivo in combo with Cisplatin and Gemcitabine for firstline treatment of adult patients with metastatic Urothelial Carcinoma: Bristol Myers Squibb Medical Dialogues, March 10, 2024	<a href="#">USFDA approves Opdivo in combo with Cisplatin and Gemcitabine for firstline treatment of adult patients with metastatic Urothelial Carcinoma: Bristol Myers Squibb</a>	Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the firstline treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common type of bladder cancer.
10 <sup>th</sup> March	Merck Foundation More Than a Mother Marks International Women's Day Together with Their Ambassadors The Week, March 10, 2024	<a href="#">Merck Foundation More Than a Mother Marks International Women's Day Together with Their Ambassadors</a>	Merck Foundation marks International Women's Day 2024 through their More Than a mother program that was launched in 2016 to empower women living with infertile through access to information, health and change of mindset. Merck



			Foundation, the philanthropic arm of Merck KGaA Germany, together with Africa's First Ladies, who are their ambassadors, mark International Women's Day 2024, through their historic campaign More Than a Mother.
11 <sup>th</sup> March	In Memoriam: Ranjit Shahani The Financial Express, March 11, 2024	<a href="#">In Memoriam: Ranjit Shahani</a>	A healthcare industry veteran, Shahani was President Emeritus of Organisation of Pharmaceuticals Producers of India (OPPI), President Emeritus, Swiss Indian Chamber of Commerce and played a key role in promoting strong ties between Switzerland and India.
11 <sup>th</sup> March	Cut-price malaria vaccine to begin Africa rollout from May ET Health World, March 11, 2024	<a href="#">Cut-price malaria vaccine to begin Africa rollout from May</a>	The R21 vaccine, a three-dose course and booster shot for children aged 536 months, is the second malaria shot approved by the WHO. But researchers say it will be cheaper than the other vaccine produced by British pharma giant GlaxoSmithKline. The WHO said its rollout was expected to greatly expand supply to meet high demand from African countries.
11 <sup>th</sup> March	Serum looks beyond Covid with new vaccines for malaria, dengue: CEO Business Standard, March 11, 2024	<a href="#">Serum looks beyond Covid with new vaccines for malaria, dengue: CEO</a>	Serum produces AstraZeneca's Covid19 vaccine under the brand name Covishield in India, and also makes Novavax's protein based Covid shots. It invested \$2 billion during the peak of the global health crisis to boost production. The company currently sells about 1.5 billion total vaccine doses every year and estimates a total production capacity of as much as 4 billion doses.
12 <sup>th</sup> March	AstraZeneca, Mankind Pharma partner for distribution of asthma medication Business Standard, March 12, 2024	<a href="#">AstraZeneca, Mankind Pharma partner for distribution of asthma medication</a>	In a move aimed at addressing the growing asthma burden in India, AstraZeneca Pharma India and Mankind Pharma on Monday announced that they are collaborating to exclusively distribute AstraZeneca's asthma medication, Symbicort (inhaler), in India.
12 <sup>th</sup> March	GlaxoSmithKline Pharmaceuticals Ltd slips for fifth straight session Business Standard, March 12, 2024	<a href="#">GlaxoSmithKline Pharmaceuticals Ltd slips for fifth straight session</a>	GlaxoSmithKline Pharmaceuticals Ltd is quoting at Rs 2049.1, down 0.04% on the day as on 13:19 IST on the NSE. The stock jumped 26.97% in last one year as compared to a 30.56% rally in NIFTY and a 66.46% spurt in the Nifty Pharma index.
13 <sup>th</sup> March	Pharma industry bodies welcome govt s technical upgradation scheme Business Standard, March 13, 2024	<a href="#">Pharma industry bodies welcome govt s technical upgradation scheme</a>	Highlighting the broadened eligibility criteria of the scheme, Anil Matai, director general, Organisation of Pharmaceutical Producers of India (OPPI) said initially the scheme covered only micro, small and

			medium enterprises (MSMEs), having annual turnover of up to Rs 250 crore.
13 <sup>th</sup> March	Pharma Industry Townhall to be held in Mumbai Express Pharma, March 13, 2024	<a href="#">Pharma Industry Townhall to be held in Mumbai</a>	Keynote address: Anil Matai, Director General of OPPI will deliver a keynote address that will provide valuable insights into the current trends and challenges facing the industry. Storytelling in pharma and healthcare communication: Cherojit Goswami and Atin Roy from Ogilvy will share their experiences around the art of storytelling in pharma and healthcare communication, emphasising its importance in engaging audiences effectively.
13 <sup>th</sup> March	Novo Nordisk owner to expand in India this year The Print, March 13, 2024	<a href="#">Novo Nordisk owner to expand in India this year</a>	It has seen a surge in revenue from Novo Nordisk, the maker of blockbuster obesity drug Wegovy and diabetes treatment Ozempic. The firm, whose assets under management rose to 149 billion euros (\$163 billion) at the end of 2023 from 108 billion a year earlier, manages a portfolio of 170 companies across life sciences and capital investments in equities, fixed-income assets, and real estate.
13 <sup>th</sup> March	In a stress-filled world, know your LDL numbers by heart The Times of India, March 13, 2024	<a href="#">In a stress-filled world, know your LDL numbers by heart</a>	Bedi was speaking during a recent event held to create awareness about the dangers of LDL (or 'bad') cholesterol. Organised as a part of a joint campaign by global pharma major Novartis and The Times of India, the 'Unblocked and Beat Bad Cholesterol' drive saw 300 people turn up for a fitness session led by Mandira.
13 <sup>th</sup> March	Ozempic may slow down kidney disease progression: Does new trial hold out hope for other health conditions The Indian Express, March 13, 2024	<a href="#">Ozempic may slow down kidney disease progression: Does new trial hold out hope for other health conditions</a>	Now Eli Lilly, which markets tirzepatide (dual GIPGLP1 compound) under the names Mounjaro and Zepbound, is also enrolling patients for its own clinical trial to find out if its injectable can treat CKD in people with obesity, both with and without Type 2 diabetes.
14 <sup>th</sup> March	Pharmaceutical bodies welcome uniform marketing code The Economic Times, March 14, 2024	<a href="#">Pharmaceutical bodies welcome uniform marketing code</a>	A high-level committee formed under Niti Aayog's VK Paul also held meetings with the representatives of pharma lobby groups to review the matter. Members of the OPPI, IPA IDMA attended the meeting on November 4 last year. The panel was formed by health minister Mansukh Mandaviya after reports suggested that companies were spending exorbitantly on promotion of drugs.

14 <sup>th</sup> March	Manipal Hospitals backer Novo Holdings to expand in India, open Mumbai office VC Circle, March 14, 2024	<a href="#">Manipal Hospitals backer Novo Holdings to expand in India, open Mumbai office</a>	Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, plans to open an office in India this year to tap innovation and a growing healthcare market, its CEO Kasim Kutay said on Tuesday. The firm, whose assets under management rose to 149 billion euros (\$163 billion) at the end of 2023 from 108 billion a year earlier, manages a portfolio of 170 companies across life sciences and capital investments in equities, fixed-income assets, and real estate.
14 <sup>th</sup> March	Emcure to Distribute Sanofi's Cardiac Brands Here The Economic Times, March 14, 2024	<a href="#">Emcure to Distribute Sanofi's Cardiac Brands Here</a>	Sanofi India, the local unit of French drugmaker Sanofi, on Wednesday said it has entered into an exclusive distribution and promotion agreement with Emcure for its cardiovascular products in India. The financial details of the deal were not disclosed.
14 <sup>th</sup> March	Pfizer Ltd slips for fifth straight session Business Standard, March 14, 2024	<a href="#">Pfizer Ltd slips for fifth straight session</a>	Pfizer Ltd is quoting at Rs 4217.85, down 2.23% on the day as on 13:19 IST on the NSE. The stock jumped 81.79% in last one year as compared to a 29.63% rally in NIFTY and a 60.88% spurt in the Nifty Pharma index. Pfizer Ltd dropped for a fifth straight session today.
14 <sup>th</sup> March	Sanofi India, Emcure Pharma announce exclusive distribution partnership Business Standard, March 14, 2024	<a href="#">Sanofi India, Emcure Pharma announce exclusive distribution partnership</a>	Sanofi India and Emcure Pharmaceuticals on Monday announced an exclusive distribution and promotion agreement for Sanofi's cardiovascular products in India. Effective immediately, Emcure Pharmaceuticals will exclusively distribute and promote Sanofi India s Cardiovascular brands including Cardace, Clexane, Targocid, Lasix, and Lasilactone.
14 <sup>th</sup> March	Chronic kidney disease on rise due to negligence towards regular health checkups, say experts The Print, March 14, 2024	<a href="#">Chronic kidney disease on rise due to negligence towards regular health checkups, say experts</a>	The rising instances of chronic kidney disease (CKD) are a result of negligence towards regular health check-ups and not taking diabetes seriously, experts said on Wednesday. A panel discussion was organised by pharmaceutical company Bayer on the eve of 'World Kidney Day'.
15 <sup>th</sup> March	WNS opens new delivery centre in Hyderabad, AstraZeneca GCC to up headcount by 30% at Chennai The Financial Express, March 15, 2024	<a href="#">WNS opens new delivery centre in Hyderabad, AstraZeneca GCC to up headcount by 30% at Chennai</a>	Meanwhile, AstraZeneca India Private Limited, the Global Capability Centre of drug maker AstraZeneca, has announced its plan to expand the scope of its Global Innovation and Technology Centre (GITC) in Chennai, including growing headcount by about 30 percent across information



			technology, software and business services over next two years.
15 <sup>th</sup> March	Novartis set to launch chronic myeloid leukemia drug in India Live Mint, March 15, 2024	<a href="#">Novartis set to launch chronic myeloid leukemia drug in India</a>	Novartis India, the local arm of Swiss pharma giant Novartis AG, is in discussions to secure a distribution partner for the imminent launch of Asciminib, the first-in-class treatment for chronic myeloid leukemia (CML) targeting the ABL myristoyl pocket (STAMP), Amitabh Dube, the company's country president and managing director, said.
15 <sup>th</sup> March	Sanofi India inks distribution pact with Emcure, but shares trade flat Money Control, March 15, 2024	<a href="#">Sanofi India inks distribution pact with Emcure, but shares trade flat</a>	Shares of Sanofi India stayed flat in the opening trade on March 14 after the company signed an agreement with Emcure Pharmaceuticals to distribute its products. At 9:18am, Sanofi India was quoting Rs 8,028.50, up Rs 12.05, or 0.15 percent, on the BSE.
15 <sup>th</sup> March	Slow Down for kidney health as India's CKD on the rise PharmaBiz, March 15, 2024	<a href="#">Slow Down for kidney health as India's CKD on the rise</a>	The Bayer and ISN joint campaign #ReadyToSlowDown was launched in India last November as an urgent call to action for the 101 million people (11.4% of the country's population) living with diabetes to pay closer attention to their kidney health.
15 <sup>th</sup> March	AstraZeneca to expand global tech centre in Chennai DT Next, March 15, 2024	<a href="#">AstraZeneca to expand global tech centre in Chennai</a>	AstraZeneca India Private Limited (AZIPL), the Global Capability Centre of AstraZeneca, announced on Thursday its plan to expand the scope of its Global Innovation and Technology Centre (GITC) in Chennai, including growing headcount by about 30 per cent across information technology, software, and business services over next two years
16 <sup>th</sup> March	-	-	-
17 <sup>th</sup> March	CDSCO Panel Grants Roche's Protocol Amendment Proposal For Crovalimab study Medical Dialogues, March 17, 2024	<a href="#">CDSCO Panel Grants Roche's Protocol Amendment Proposal For Crovalimab study</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Roche's protocol amendment proposal for the clinical trial titled A study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab in pediatric participants with the atypical hemolytic uremic syndrome (aHUS) (COMMUTEp).
17 <sup>th</sup> March	CDSCO Panel grants Pfizer's Protocol Amendment for Anticancer Drug Palbociclib study	<a href="#">CDSCO Panel grants Pfizer's Protocol Amendment for Anticancer Drug Palbociclib study</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Pfizer's

	Medical Dialogues, March 17, 2024		protocol amendment proposal for the clinical trial titled Study of Palbociclib Combined with Chemotherapy in Pediatric Patients With Recurrent/Refractory Solid Tumors.
18 <sup>th</sup> March	Medical devices makers worried over wider price controls in the offing The Financial Express, March 18, 2024	<a href="#">Medical devices makers worried over wider price controls in the offing</a>	We emphasise the importance of striking a balance between affordability and innovation, ensuring that patients have access to lifesaving treatments while incentivising continued research and development. Companies investing substantially in R&D must be empowered to recoup their investments, said Anil Matai, director general at Organisation of Pharmaceutical Producers of India (OPPI).
18 <sup>th</sup> March	Fake cancer medicines coming from Bangladesh are spreading death in India Aaj Tak, March 18, 2024	<a href="#">Fake cancer medicines coming from Bangladesh are spreading death in India</a>	Due to lack of information, State Insurance Corporation and many other government institutions also purchase such medicines for the patients. According to the report, Organization of Pharmaceutical Producers of India (OPPI) has complained about this to the government, after which the Central Government has assured to take action on it.
18 <sup>th</sup> March	Medical devices makers worried over wider price controls in the offing The Financial Express, March 18, 2024	<a href="#">Medical devices makers worried over wider price controls in the offing</a>	We emphasise the importance of striking a balance between affordability and innovation, ensuring that patients have access to lifesaving treatments while incentivising continued research and development. Companies investing substantially in R&D must be empowered to recoup their investments, said Anil Matai, director general at Organisation of Pharmaceutical Producers of India (OPPI).
18 <sup>th</sup> March	Modify Clinical study protocol of Iptacopan study in aHUS: CDSCO Panel Tell Novartis Medical Dialogues, March 18, 2024	<a href="#">Modify Clinical study protocol of Iptacopan study in aHUS: CDSCO Panel Tell Novartis</a>	Reviewing the Phase IIIb clinical trial study protocol of Iptacopan, the Subject Expert Committee (SEC) functional under the Central Standard Drug Control Organisation (CDSCO) has opined the drug major Novartis to modify the protocol in line with the inclusion criteria, the duration for which the study drug will be provided to participants, exclusion criteria, and others.
18 <sup>th</sup> March	Need More Justification: CDSCO Panel rejects J&J protocol amendment proposal for Teclistamab study Medical Dialogues, March 18, 2024	<a href="#">Need More Justification: CDSCO Panel rejects J&amp;J protocol amendment proposal for Teclistamab study</a>	Citing that more justification is required, the Subject Expert Committee SEC functional under the Central Drug Standard Control Organisation (CDSCO) has rejected Johnson & Johnson's protocol

			amendment proposal for the anticancer drug Teclistamab study.
18 <sup>th</sup> March	AstraZeneca Gets CDSCO Panel Nod to Study anticancer drug Volrustomig Medical Dialogues, March 18, 2024	<a href="#">AstraZeneca Gets CDSCO Panel Nod to Study anticancer drug Volrustomig</a>	The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the study of the anticancer drug Volrustomig (MEDI5752). This came after the drug maker AstraZeneca presented phase III clinical study protocol No. D798EC00001.
19 <sup>th</sup> March	MedTech industry wary about new pricing framework proposal Medical Buyer, March 19, 2024	<a href="#">MedTech industry wary about new pricing framework proposal</a>	We emphasise the importance of striking a balance between affordability and innovation, ensuring that patients have access to lifesaving treatments while incentivising continued research and development. Companies investing substantially in R&D must be empowered to recoup their investments, said Anil Matai, director general at Organisation of Pharmaceutical Producers of India (OPPI).
19 <sup>th</sup> March	Medical device makers worried over price caps The Financial Express, March 19, 2024	<a href="#">Medical device makers worried over price caps</a>	“We emphasise the importance of striking a balance between affordability and innovation, ensuring that patients have access to life-saving treatments while incentivising continued research and development,” said Anil Matai, director-general at Organisation of Pharmaceutical Producers of India (OPPI).
19 <sup>th</sup> March	Roche Information Solutions plans to expand team’s strength to 1300 BioSpectrum India, March 19, 2024	<a href="#">Roche Information Solutions plans to expand team’s strength to 1300</a>	Roche’s first Digital Center of Excellence in India plans to expand and develop the organisation with an expected workforce totalling to 1300. Raja Jamalamadaka (as seen in the image), Managing Director, Roche Information Solutions (RIS) India, said that housed in a 200,000 square feet area and growing from 36 employees during its inception to over 350 employees at present, RIS India is a colocation for Roche Information Solutions, Roche Diagnostics Solutions R&D, and Roche Informatics teams encompassing a diverse team of professionals from data engineers and software engineers to architects and user-experience professionals.
19 <sup>th</sup> March	P&G India appoints Kumar Venkatasubramanian as CEO Hindustan Times, March 19, 2024	<a href="#">P&amp;G India appoints Kumar Venkatasubramanian as CEO</a>	Leading FMCG maker P&G India on Monday announced the appointment of Kumar Venkatasubramanian as CEO, with effect from May 1, 2024. Kumar Venkatasubramanian(X) The current CEO,

			L V Vaidyanathan will leave the company to pursue personal interests after 28 years of service, a statement from P&G India said.
19 <sup>th</sup> March	P&G Health to expand its VMS portfolio Live Mint, March 19, 2024	<a href="#">P&amp;G Health to expand its VMS portfolio</a>	Procter & Gamble Health Ltd, a subsidiary of the multinational consumer goods firm Procter & Gamble, is preparing to expand its portfolio of vitamins, minerals, and supplements (VMS), especially neurotrophic vitamins, under its five-year plan, Milind Thatte, MD of the company, said.
20 <sup>th</sup> March	Pfizer Gets CDSCO Panel Nod To study Osivelotor in sickle cell disease Medical Dialogues, March 20, 2024	<a href="#">Pfizer Gets CDSCO Panel Nod To study Osivelotor in sickle cell disease</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to drug major Pfizer to conduct the phase 2/3 clinical trial of Osivelotor (also known as PF07940367 or GBT021601), 25mg and 100mg tablets in participants with sickle cell disease.
21 <sup>st</sup> March	Why government is cracking down on junkets, gifts for doctors by pharma firms Money Control, March 21, 2024	<a href="#">Why government is cracking down on junkets, gifts for doctors by pharma firms</a>	The Association of International Pharmaceutical Producers also expressed hope in the new rules. The emphasis on informational and educational items, with a capped value, represents a balanced approach that prioritises knowledge dissemination and enhancement, said Anil Matai, Director General, Organisation of Pharmaceutical Producers of India, (OPPI).
21 <sup>st</sup> March	India Enacts UCPMP 2024 to Curb Unethical Pharma Marketing, Industry Reacts BNN Breaking, March 21, 2024	<a href="#">India Enacts UCPMP 2024 to Curb Unethical Pharma Marketing, Industry Reacts</a>	The introduction of UCPMP 2024 has been met with applause from various quarters of the industry, with organizations like the Indian Pharmaceutical Alliance and the Organisation of Pharmaceutical Producers of India (OPPI) expressing support for the guidelines.
21 <sup>st</sup> March	Merck Healthcare signs MoU with Rajiv Gandhi Cancer Institute and Research Centre to enhance cancer care access The Financial Express, March 21, 2024	<a href="#">Merck Healthcare signs MoU with Rajiv Gandhi Cancer Institute and Research Centre to enhance cancer care access</a>	Merck India, a science and technology company, on Wednesday announced a strategic partnership with the renowned Rajiv Gandhi Cancer Institute and Research Centre under the Umeed program. According to the company's press statement, this collaborative initiative aims to bolster access to cancer care for patients affected by head & neck, and colorectal cancer.
22 <sup>nd</sup> March	vridhhi 2024: The Indian pharma industry comes together to deliberate on glorious future	<a href="#">vridhhi 2024: The Indian pharma industry comes together to deliberate on glorious future</a>	It was for the first time in the industry's history, such a mega scale event, saw enthusiastic and active collaboration from not only leading pharmaceutical

	Express Pharma, March 22, 2024		companies and strategic partners, but from other prominent industry associations as well, like Indian Pharmaceutical Alliance (IPA), Organisation of Pharmaceutical Producers of India (OPPI), and Indian Pharma Machinery Manufacturers Association (IPMMA).
22 <sup>nd</sup> March	Novartis CEO Narasimhan: India played a role in all 10 positive phase 3 trials globally in 2023 CNBC TV18, March 22, 2024	<a href="#">Novartis CEO Narasimhan: India played a role in all 10 positive phase 3 trials globally in 2023</a>	Vasant Vas Narasimhan, the Global CEO of Novartis, emphasized the pivotal role of Indian operations in the pharmaceutical giant's performance worldwide. In an exclusive interview with CNBCTV18, Narasimhan disclosed that last year, all 10 positive phase three trials conducted by Novartis were influenced by their operations in India. He specifically highlighted the significance of Novartis Hyderabad centre, which facilitated the submissions of these trials to global regulators.
22 <sup>nd</sup> March	Health News Roundup: Musk's Neura link shows first brainchip Patient Playing Online Chess; UnitedHealth says unit Change has restored and rebuilt functions handled by Amazon and more Devdis Course, March 22, 2024	<a href="#">Health News Roundup: Musk's Neura link shows first brainchip Patient Playing Online Chess; UnitedHealth says unit Change has restored and rebuilt functions handled by Amazon and more</a>	Bristol Myers Squibb said on Wednesday a combination of Opdivo and Yervoy met the main goal of a latestage study evaluating it as an initial treatment for a type of liver cancer. The results bolster the company's efforts to expand the use for the blockbuster drugs that are set to lose their market exclusivity before the end of the decade.
22 <sup>nd</sup> March	Pfizer Gets CDSCO Panel Nod to Study Anticancer Drug PF07220060 Medical Dialogues, March 22, 2024	<a href="#">Pfizer Gets CDSCO Panel Nod to Study Anticancer Drug PF07220060</a>	The drug major Pfizer has got a goahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the clinical trial of the anticancer drug PF07220060 100 mg Tablets. However, this approval is subject to the condition that justification for the sample size in India compared to the global sample size shall be submitted to CDSCO.
22 <sup>nd</sup> March	CDSCO Panel grants GSK's Updated Prescribing Information for Antibiotic FDC of Amoxicillin, Clavulanic acid Medical Dialogues, March 22, 2024	<a href="#">CDSCO Panel grants GSK's Updated Prescribing Information for Antibiotic FDC of Amoxicillin, Clavulanic acid</a>	The drug major GSK has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to update the prescribing information of the fixed dose combination (FDC) Amoxicillin Trihydrate 759.04mg eq. to Amoxicillin free acid 652.78mg plus Potassium Clavulanate 61.48mg eq. to 22 <sup>nd</sup> March Clavulanic acid 50.41mg per



			5ml powder for reconstitution into suspension.
22 <sup>nd</sup> March	Novartis has 12 medicines in launch pipeline, most of them for India over the next few years: CEO Narasimhan CNBC TV18, March 22, 2024	<a href="#">Novartis has 12 medicines in launch pipeline, most of them for India over the next few years: CEO Narasimhan</a>	Vasant Vas Narasimhan, the Global CEO of Novartis, revealed that the company has 12 medicines in the launch pipeline over the next few years. Of these upcoming launches, which are part of 10 positive phase three studies, many will be in Indian markets.
22 <sup>nd</sup> March	Novartis aims for double digit growth in India, eyes Hyderabad expansion CNBC TV18, March 22, 2024	<a href="#">Novartis aims for double digit growth in India, eyes Hyderabad expansion</a>	Novartis global CEO Vas Narasimhan on Thursday (March 21) said he is eyeing robust growth at a double digit rate in India, as the company ramps up its capabilities in research, IT, and data science, along with other core functions. I would foresee us continuing to grow at a double digit rate, as we continue to build out capabilities in R&D, IT and data science, as well as all of our core functions.
22 <sup>nd</sup> March	Pfizer's Braftovi to command 42 per cent share of BRAF inhibitors melanoma market by 2028: GlobalData Express Pharma, March 22, 2024	<a href="#">Pfizer's Braftovi to command 42 per cent share of BRAF inhibitors melanoma market by 2028: GlobalData</a>	Since Roche's Zelboraf gained (vemurafenib) FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, underscoring the significance of combating BRAF mutations in melanoma.
22 <sup>nd</sup> March	Merck Healthcare signs MoU with RGCIRC to enhance cancer care access Express Healthcare, March 22, 2024	<a href="#">Merck Healthcare signs MoU with RGCIRC to enhance cancer care access</a>	This collaborative initiative aims to bolster access to cancer care for patients affected by head & neck, and colorectal cancer. The Umeed Program, rooted in a multifaceted approach, seeks to empower patients, foster awareness, and be a knowledge partner to healthcare professionals, thereby catalysing positive changes in the community.
22 <sup>nd</sup> March	Health News Roundup: Bayer says 2024 sales of prostate cancer drug above \$1 billion; Becton Dickinson ramps up U.S. syringe production amid China quality concerns and more Devdis Course, March 22, 2024	<a href="#">Health News Roundup: Bayer says 2024 sales of prostate cancer drug above \$1 billion; Becton Dickinson ramps up U.S. syringe production amid China quality concerns and more</a>	Bayer says 2024 sales of prostate cancer drug above \$1 billion Bayer on Thursday predicted at least \$1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising anti blood clotting therapy.
22 <sup>nd</sup> March	Bristol Myers Squibb concludes acquisition of Karuna Therapeutics Medical Dialogues, March 22, 2024	<a href="#">Bristol Myers Squibb concludes acquisition of Karuna Therapeutics</a>	Princeton: Bristol Myers Squibb has announced that the Company has successfully completed its acquisition of Karuna Therapeutics, Inc. With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (BMS).

23 <sup>rd</sup> March	-	-	-
24 <sup>th</sup> March	-	-	-
25 <sup>th</sup> March	-	-	-
26 <sup>th</sup> March	Multinational drugmakers to seek clarity on recently issued pharma marketing code The Hindu Business Line, March 26, 2024	<a href="#">Multinational drugmakers to seek clarity on recently issued pharma marketing code</a>	The updated code is directionally good, but the Organisation of Pharmaceutical Producers of India will seek guidelines for implementation of the code, Anil Matai, OPPI Director-General, told businessline. A platform largely for multinational drug companies, OPPI has created a taskforce for identifying details that need clarity in the updated code, he said, adding that the organisation has its own ethical code, as well.
26 <sup>th</sup> March	Pandemic accord talks at loggerheads as time ticks away The Times of India, March 26, 2024	<a href="#">Pandemic accord talks at loggerheads as time ticks away</a>	Success or failure in the next pandemic may heavily depend on the pharmaceutical industry coming up with the necessary vaccines, tests and treatments and crucially, how they are then distributed. Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations industry body, said any accord would be meaningless if companies were being strongarmed.
26 <sup>th</sup> March	CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal For Anticancer Drug Osimertinib Medical Dialogues, March 26, 2024	<a href="#">CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal For Anticancer Drug Osimertinib</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major AstraZeneca's proposal of the protocol amendment of the anticancer drug Osimertinib. This came after the drug maker AstraZeneca presented a protocol amendment version 3.0 dated 20 November 2023 protocol No. D5169C00001.
27 <sup>th</sup> March	Homegrown Solution to India's Cervical Cancer Dilemma The Wire, March 27, 2024	<a href="#">Homegrown Solution to India's Cervical Cancer Dilemma</a>	Developed by the Serum Institute of India, one of the largest vaccine producers in the world, it's currently priced at half of the cost of its competitors Merck & Co's Gardasil and GlaxoSmithKline's Cervarix at 2,000 rupees per dose with plans announced to produce 200 million doses.
27 <sup>th</sup> March	Sanofi, Cipla join hands to expand reach of CNS portfolio in India Business Standard, March 27, 2024	<a href="#">Sanofi, Cipla join hands to expand reach of CNS portfolio in India</a>	Sanofi India and Cipla announced on Tuesday an exclusive partnership to boost access to Sanofi's Central Nervous System (CNS) medications across India. Cipla will leverage its extensive network to distribute Sanofi's CNS portfolio, including

			Frisium, a leading antiepileptic drug. Sanofi will retain ownership, import, and manufacture of the CNS products.
27 <sup>th</sup> March	Merck inks MoU with Amity University to ensure that the students are industryready PharmaBiz, March 27, 2024	<a href="#">Merck inks MoU with Amity University to ensure that the students are industryready</a>	Merck Life Science has inked a Memorandum of Understanding (MoU) with Amity University, Uttar Pradesh, Noida Campus. The objective behind this collaboration is to ensure that the students are industryready. Under this MoU, Practical & Industry Oriented Certificate Courses focusing on Advanced Instrumentation will be offered to the students with hands-on training opportunities.
28 <sup>th</sup> March	Dr Reddy's to Promote, Distribute Sanofi Vaccine Brands in India The Economic Times, March 27, 2024	<a href="#">Dr Reddy's to Promote, Distribute Sanofi Vaccine Brands in India</a>	Dr Reddy's Laboratories (DRL) on Wednesday said it has entered into an exclusive partnership to promote and distribute Sanofi Healthcare India's vaccine brands across the country. The announcement comes a day after Sanofi Healthcare India announced a separate partnership with Cipla to boost access to Sanofi's central nervous system medication across India.
28 <sup>th</sup> March	AstraZeneca Pharma rises 4% on getting CDSCO nod to import cancer treatment drug Money Control, March 28, 2024	<a href="#">AstraZeneca Pharma rises 4% on getting CDSCO nod to import cancer treatment drug</a>	AstraZeneca Pharma India Limited has received permission to import cancer treatment drug Trastuzumab deruxtecan lyophilized powder. Shares of AstraZeneca Pharma India jumped over 4 percent on March 27, a day after the company informed that it has received permission to import, for sale and distribution, Trastuzumab deruxtecan lyophilized powder concentrate for solution for infusion 100mg (Enhertu) from the Central Drugs Standard Control Organisation.
28 <sup>th</sup> March	Bayer working on Phase 3 trials for Finerenone as potential treatment for heart failure, non-diabetes CKD ET Health World, March 28, 2024	<a href="#">Bayer working on Phase 3 trials for Finerenone as potential treatment for heart failure, non-diabetes CKD</a>	Bayer working on Phase 3 trials for Finerenone as potential treatment for heart failure, non-diabetes CKD Finerenone is a first-in-class nonsteroidal, selective mineralocorticoid receptor antagonist indicated for patients with Chronic Kidney Disease (CKD) associated with type 2 diabetes.
28 <sup>th</sup> March	Dr Reddy s partners with Sanofi India to distribute vaccine brands in India Business Standard, March 28, 2024	<a href="#">Dr Reddy s partners with Sanofi India to distribute vaccine brands in India</a>	Dr. Reddy/s Laboratories Limited (DRL) has entered into an exclusive distribution partnership with Sanofi Healthcare India to promote and distribute their vaccine brands across private markets in the country. The pact is aimed at expanding the availability of Sanofi s vaccine brands,

			both paediatric and adult, within private markets in India. Click here to follow our WhatsApp channel.
29 <sup>th</sup> March	-	-	-
30 <sup>th</sup> March	AstraZeneca drug gets CDSCO nod to treat two more cancers The Hindu, March 30, 2024	<a href="#">AstraZeneca drug gets CDSCO nod to treat two more cancers</a>	AstraZeneca Pharma India has received nod from the Central Drugs Standard Control Organisation (CDSCO) to import for sale and distribution Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100 mg (Enhertu) for treating two more cancers.
31 <sup>st</sup> March	-	-	-

---